MAVACAMTEN IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Abstract

Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases, affecting between 0.16% and 0.29% of the general adult population. It is a genetic disease of the myocardium and is characterized by marked myocardial hypertrophy that cannot be explained by the pressure load or the presence of myocytic disorder. Objectives: to analyze the effectiveness of mavacamten in the treatment of HCM according to high-quality studies already available in the literature. Materials and methods: This is an integrative review, in which the guiding question was “Is mavacamten an effective drug in the treatment of obstructive hypertrophic cardiomyopathy?”. The search for articles was performed in the PubMed database using the terms “mavacamten” and “hypertrophic obstructive cardiomyopathy”, combined with Boolean operators. Results and Discussion: Treatment with mavacamten improved exercise capacity, left ventricular outflow tract obstruction, New York Heart Association functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. Mavacamten was associated with favorable changes in cardiac structure and function over 30 weeks of therapy, including improvement in echocardiographic markers of left ventricular filling pressures, left ventricular outflow tract gradients, and systolic forward motion. Conclusion: Mavacamten significantly improved measures of left ventricular diastolic function and systolic anterior motion, in addition, mavacamten significantly improved quality of life among patients with symptomatic obstructive hypertrophic cardiomyopathy.